Management Strategies for Hypertensive Nephropathy in CKD Patients
Overview As a clinical pharmacist, effective BP management in CKD is essential to slow …
Don't use DIABETES as a CV risk equivalent
As a pharmacy doctor, you will see more consensus on using statins for diabetes patients.…
Optimizing meds in patients with HFrEF and CKD
Few patients with chronic kidney disease (CKD) are on optimized meds for heart failure w…
DAPT after an ischemic stroke or TIA?
Overview New data will raise questions about optimal use of short-term dual antiplatele…
Know COLCHICINE's role in chronic coronary disease
Overview As a cardiovascular pharmacist, you’ll hear buzz about new Rx colchicine ( Lo…
FAQs on First-Line BP Meds
Introduction As a clinical pharmacist, you often encounter questions about choosing bl…
Guide use of BP meds during pregnancy
As a cardiovascular pharmacist, more questions arise about managing chronic hypertension …
Angiotensin-converting enzyme (ACE) inhibitors
Therapeutic actions ACE inhibitors block ACE in the lungs from converting angiotensin 1…
HFpEF Treatment Options
Overview As a clinical pharmacy specialist, you will get questions about managing hea…
DAPT duration for patients at HIGH bleeding risk
Overview As a cardiovascular pharmacist, you will hear debate about shorter dual antip…
Can we use fondaparinux in RENAL patients?
Overview As a clinical pharmacy specialist, it is important to address the safety of …
Think "LOWER IS BETTER" for LDL in high CV risk patients
Overview As a cardiovascular pharmacist, there is an ongoing debate regarding the nece…
Coenzyme Q10 for STATIN intolerance
Introduction As a community pharmacist, patients will ask you more about Coenzyme Q10 …